Condition
Angina Pectoris, Stable
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Unknown1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02710435Active Not Recruiting
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
NCT04408261Phase 2Unknown
BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome
NCT03866395Phase 4CompletedPrimary
Effects of Ivabradine on Residual Myocardial Ischemia After PCI
NCT01826994Not ApplicableCompleted
Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome
Showing all 4 trials